Your Regulator Probably Isn't a WHO Listed Authority. Here's Why That Now Matters for Exports.

Quick answer

A WHO Listed Authority for medical devices is a regulator whose device assessments other authorities may rely on rather than repeat. WHO published the first such list on 14 July 2026 — twelve authorities holding transitional status (tWLAs-MD), including the US FDA, each scoped to medical devices including in vitro diagnostics [1, 2, 3]. This is a reliance enabler, not a passport. It means other countries' regulators now have a WHO-published reference point identifying whose device assessments they may build on. It does not oblige any regulator to accept an FDA clearance, does not create automatic registration anywhere, and does not change how you obtain clearance. WHO states explicitly that responsibility for using the list rests with the users — regulators and procurement agencies — and depends on the context of intended use [3].

What WHO actually published

On 14 July 2026 WHO published the list of transitional WHO Listed Authorities for medical devices, current as of 1 July 2026 [2, 3]. WHO described it in a departmental update issued 23 July 2026 [1].

Twelve authorities are listed, every one with the same designated scope — medical devices including in vitro diagnostics [3]:

#	Country / region	Authority
1	Australia	Therapeutic Goods Administration (TGA)
2	Brazil	Brazilian Health Regulatory Agency (ANVISA)
3	Canada	Health Canada
4	China	National Medical Products Administration (NMPA)
5	EU / EEA-EFTA	European Medical Devices Regulatory Network
6	Republic of Korea	Ministry of Food and Drug Safety (MFDS)
7	Japan	MHLW / Pharmaceuticals and Medical Devices Agency (PMDA)
8	Russian Federation	Ministry of Health
9	Switzerland	Swissmedic
10	Singapore	Health Sciences Authority (HSA)
11	United Kingdom	Medicines and Healthcare products Regulatory Agency (MHRA)
12	United States	Food and Drug Administration (FDA)

The European entry is a network rather than a single agency, comprising the European Commission and the regulatory authorities of 30 EU/EEA-EFTA countries [3].

WHO built the list from two existing sources rather than from fresh assessments: the Recognized Regulatory Authorities list maintained by WHO Prequalification for medical devices, and membership of the Management Committee of the International Medical Device Regulators Forum (IMDRF) as of 30 June 2026 [3]. No authority was individually evaluated to get onto this list. That is the whole point of the word transitional.

The correction most coverage gets wrong

Two errors are circulating, and if you repeat either in front of a regulator you will look like you read a press release instead of the document.

The FDA's 2024 WLA designation was not about devices. WHO designated the US FDA a WHO Listed Authority in May 2024, in a round covering 33 authorities [7]. That designation, and the wider WLA framework as originally launched, covered medicines and vaccines. Medical devices and IVDs sat outside it. The July 2026 tWLA-MD list is the first time device regulation enters this framework at all — and it enters as an interim arrangement, not a designation.

The two lists were built in completely different ways, and this is the distinction to hold onto. The 2024 medicines designations followed WHO performance evaluations, recommended by WHO's technical advisory group on WHO Listed Authorities, confirming advanced performance against international standards [7]. The 2026 device list involved no such evaluation. WHO assembled it from its existing Prequalification recognition list and IMDRF Management Committee membership as of 30 June 2026 [3]. One list was earned through assessment; the other was derived from existing standing. Treating them as equivalent is the single most common error in coverage of this announcement.

The five-year clock has not started. Widely reported as "valid for five years from publication," the document says something different: the tWLA-MD is a risk-based evaluation process valid for five years from the date of publication of the WHO guidance on the process and requirements for performance evaluation of candidate WLAs-MD [3]. That guidance is not out yet. The clock starts when it lands, and nobody currently knows when that is.

What "regulatory reliance" actually means

Reliance is the mechanism this list exists to support, and it is more modest than it sounds.

WHO defines the practice as regulators making use of evaluations, inspections and other regulatory decisions already conducted by other regulators, where appropriate, while remaining fully responsible for their own decisions [1]. Rather than repeating the same scientific assessment independently, an authority can build on work already done.

Three features follow from that definition, and they are the whole story for an exporter:

• It is permissive, not mandatory. No regulator is obliged to rely on anything. Reliance is a discretionary tool each authority chooses whether and how to use.
• Responsibility does not transfer. The relying authority still owns its decision. It can still ask for more, and frequently will.
• Scope is unsettled. WHO states that the precise scope of designation for each tWLA-MD will be defined later, in agreement with each authority, as part of the roadmap toward full WLA designation [3].

So the practical effect today is that a national regulator considering a reliance pathway has a WHO-published answer to "whose decisions are defensible to build on." That is genuinely useful to them. It is not a change in your rights.

What this means if you manufacture outside the twelve

This is the situation most exporters are actually in. India's CDSCO, Türkiye's TİTCK, Malaysia's MDA, Taiwan's TFDA and Saudi Arabia's SFDA are all absent from the list.

If you manufacture in one of those countries, the asymmetry is now written down in a WHO document: your domestic approval is not a recognised reference point abroad, and an FDA clearance is. That was informally true before. It is now formally legible to every regulator and procurement agency that consults the list.

The practical consequences:

• A clearance from a listed authority becomes a more portable asset than a domestic approval, in any market operating a reliance pathway.
• Procurement agencies are named by WHO as users of the list [3]. Tender eligibility, not just registration, is in play.
• The gap is likely to widen rather than close, because the framework is designed to expand through evaluation, and evaluation takes years.

None of this makes a domestic approval worthless — it remains what lets you sell at home. It means that if your growth plan depends on export, the authority you clear with matters more than it used to.

What this means if you already hold FDA clearance

Modestly good news, correctly understood.

Your clearance has not changed. What has changed is that its status as a reference decision is now published by WHO rather than assumed. When you approach a regulator in a reliance-operating market, you are pointing at a WHO-listed authority rather than making an argument about the FDA's reputation.

Concretely, that helps in three places: registration dossiers in markets with abridged or verification pathways, tender and procurement submissions where WHO frameworks carry weight, and conversations with distributors who need to justify why your device should be prioritised.

What it does not do is shorten any specific national process automatically. Whether your FDA clearance reduces work in Malaysia or Brazil or the Gulf depends entirely on that country's own reliance rules, which are unchanged by this list.

You will still need to evidence your FDA status in a form a foreign regulator accepts, which in most cases means an FDA export certificate — a Certificate to Foreign Government — rather than the clearance letter itself. Requirements vary by destination market and are worth confirming early, because certificate lead times are a common cause of slipped registration dates.

What to do now

If you are already pursuing FDA clearance: nothing changes in your submission. Note the development for your commercial narrative and revisit which export markets now look more accessible.

If you are weighing FDA against other markets: this modestly strengthens the case for FDA as a first or early clearance, because it is a listed authority whose decisions travel. Weigh that against cost and your actual sales pipeline, not against the announcement. If you already hold CE Mark, what actually transfers to a 510(k) is the more useful starting question.

If you are exporting from a non-listed country: map your target markets against their reliance pathways. Some publish explicit abridged routes for devices approved by reference authorities; others have nothing. That mapping determines whether an FDA clearance shortens your path or merely strengthens your position.

If you sell into tenders: check whether WHO frameworks are referenced in your procurement criteria, since WHO names procurement agencies as intended users [3].

That market-by-market mapping is the unglamorous work, and it is where the value sits: reliance rules are published inconsistently, change without announcement, and rarely say "reliance" anywhere in the text. Complizen maintains that mapping alongside FDA submission work, with regulatory experts who have direct FDA submission experience reviewing the analysis before it informs a market strategy.

Common misreadings

"The FDA has been WHO-approved." WHO listed the FDA as a transitional reference authority for devices. It did not approve, accredit or endorse it. The FDA's separate WLA designation for medicines and vaccines dates from May 2024 [7].

"My FDA clearance is now valid in 12 countries." No. The list identifies whose assessments may be relied upon by others. It grants no market access anywhere.

"This replaces national registration." It does not. Every listed market still runs its own registration process.

"The scope is settled." WHO states scope will be defined later with each authority [3].

"This is permanent." It is explicitly transitional, and authorities move off it onto the permanent WLA list by completing an evaluation [2, 3].

Frequently asked questions

What is a WHO Listed Authority for medical devices? A WHO Listed Authority for medical devices is a regulatory authority WHO has identified as having demonstrated established regulatory performance in device oversight, so that other regulators can use its assessments as a reference point for regulatory reliance. As of July 2026 no authority holds full WLA status for devices. Twelve hold transitional status (tWLA-MD), an interim arrangement while WHO finalises the full evaluation pathway [1, 3].

Is the FDA a WHO Listed Authority? For medicines and vaccines, yes — the FDA was designated a WLA in May 2024 [7]. For medical devices, the FDA holds transitional status on the tWLA-MD list published 14 July 2026, which is an interim designation rather than a completed evaluation [3].

Does this mean my FDA clearance is accepted in other countries? No. The list gives other regulators a WHO-published reference point identifying authorities whose decisions they may rely on. Each regulator decides independently whether and how to use it, and remains fully responsible for its own decision [1, 3]. Market access still requires meeting each country's registration requirements.

Which authorities are on the tWLA-MD list? Twelve: TGA (Australia), ANVISA (Brazil), Health Canada, NMPA (China), the European Medical Devices Regulatory Network, MFDS (Korea), MHLW/PMDA (Japan), the Russian Ministry of Health, Swissmedic, HSA (Singapore), MHRA (UK) and the US FDA. All are designated for medical devices including in vitro diagnostics [3].

Is India's CDSCO on the list? No. CDSCO is not among the twelve, and neither are Türkiye's TİTCK, Malaysia's MDA, Taiwan's TFDA or Saudi Arabia's SFDA. For manufacturers in those countries, a clearance from a listed authority is currently more portable than a domestic approval in markets that operate reliance pathways.

How long does transitional status last? The document states the tWLA-MD is valid for five years from publication of WHO's guidance on the process and requirements for performance evaluation of candidate WLAs-MD [3]. That guidance has not been published, so the five-year period has not begun. Reports of "five years from July 2026" are inaccurate.

How did WHO decide who was on the list? It did not run new assessments. The list was built from WHO Prequalification's existing Recognized Regulatory Authorities list for medical devices and membership of the IMDRF Management Committee as of 30 June 2026 [3].

Does this cover in vitro diagnostics? Yes. All twelve entries carry the scope "medical devices including in vitro diagnostics" [3]. This differs from the original WLA framework for medicines and vaccines, which excluded devices and IVDs.

What is regulatory reliance? Regulatory reliance is where an authority makes use of evaluations, inspections and other regulatory decisions already conducted by another regulator, rather than repeating the same scientific assessment, while remaining fully responsible for its own decision [1]. It reduces duplication but does not transfer accountability.

Should this change my regulatory strategy? Only at the margin. It modestly strengthens the case for clearing with a listed authority if export is central to your plan, particularly if you manufacture in a country that is not listed. It does not change how you obtain clearance, and it creates no automatic access. Decisions should follow your target markets' actual reliance rules, which this list does not alter.

Key takeaways

This is an interim list, not a designation. The tWLA-MD arrangement is explicitly a bridge while WHO finalises the full WLA evaluation pathway for devices [2, 3]. No authority has completed a device evaluation.

Devices were previously outside the WLA framework entirely. The FDA's 2024 WLA status covered medicines and vaccines [7]. July 2026 is the first time device regulation enters the framework.

Reliance is permissive and responsibility does not transfer. Regulators may build on a listed authority's work, but each remains fully responsible for its own decision [1], and WHO places responsibility for using the list on the user [3].

The real signal is for manufacturers outside the twelve. If your domestic regulator is not listed, the portability gap between a domestic approval and a listed-authority clearance is now formally documented — and relevant to procurement as well as registration.

The five-year clock has not started. It runs from publication of WHO's evaluation guidance, which is still pending [3]. Treat any stated end date with suspicion.

---

Whether this changes your market sequencing depends on the reliance rules in the specific countries you sell into — which is a mapping exercise, not a headline. Complizen's regulatory strategy engagement covers FDA pathway selection alongside target-market analysis, reviewed by senior FDA regulatory professionals. See how the strategy service works →

References

1. WHO — WHO advances global regulatory cooperation with first interim list of regulatory authorities for medical devices (23 July 2026). https://www.who.int/news/item/23-07-2026-who-advances-global-regulatory-cooperation-with-first-interim-list-of-regulatory-authorities-for-medical-devices
2. WHO — List of transitional WLAs for medical devices (publication record, 14 July 2026). https://www.who.int/publications/m/item/list-of-transitional-wlas-for-medical-devices
3. WHO — List of transitional WHO Listed Authorities for medical devices (tWLAs-MD) as of 1 July 2026 (PDF). https://cdn.who.int/media/docs/default-source/medicines/regulatory-systems/wla/list-of-transitional-wlas_md.pdf
4. WHO — WHO-Listed Authority (WLA) initiative. https://www.who.int/initiatives/who-listed-authority-reg-authorities
5. WHO — WHO Listed Authorities: questions and answers. https://www.who.int/news-room/questions-and-answers/item/who-listed-authorities
6. WHO — WLA Policy document (second edition, draft, PDF). https://cdn.who.int/media/docs/default-source/medicines/regulatory-systems/wla/wla-policy_draft_second-edition.pdf
7. WHO — Largest number of regulatory agencies for medical products approved as WHO Listed Authorities (20 May 2024). https://www.who.int/news/item/20-05-2024-largest-number-of-regulatory-agencies-for-medical-products-approved-as-who-listed-authorities
8. WHO — WHO designates new WHO-Listed Authorities (7 August 2025). https://www.who.int/news/item/07-08-2025-who-designates-new-who-listed-authorities--strengthening-global-access-to-quality-assured-medical-products
9. ANVISA — The World Health Organization publishes list containing regulatory authorities for medical devices. https://www.gov.br/anvisa/en/updates/the-world-health-organization-publishes-list-containing-regulatory
10. RAPS — WHO announces first global list of medical device regulators eligible for listed authority standing. https://www.raps.org/resource/who-announces-first-global-list-of-medical-device-regulators-eligible-for-listed-authority-status.html